Telix Pharmaceuticals Limited’s Post

At Capgemini, we're all about transforming data and research into real results, pushing pharma into the future while caring for humanity. That’s why we're thrilled to be part of BioTechX Europe 2024, showcasing our R&D, Clinical Development, GenAI, and pharma innovation capabilities and expertise. 🌟 What's BioTechX Europe? BioTechX Europe is the go-to event for diagnostics, precision medicine, and digital transformation in pharma and healthcare. This year, it's back in Basel, Europe’s pharma hub, on October 9 and 10, bringing together:  - 3,500+ attendees  - 400+ speakers  - 50+ start-ups The event is packed with networking opportunities and insights from top pharmaceutical and biotech companies, healthcare systems providers, start-ups and academic groups. If you want to know more, please visit: https://lnkd.in/dGcQqSQd Join us to explore the future of pharma and healthcare! 🚀 #BioTechX #PharmaInnovation #DigitalTransformation #ClinicalDevelopment #GenAI #Healthcare #Researchanddevelopment

🌐 Join us in welcoming our esteemed speaker, Mr. Naresh Kumar Gaur, Sr. Vice President MF, Amneal Pharmaceuticals to the Cutting Edge of Biopharma Innovation Summit! 🌐 India is emerging as a global leader in the biopharma landscape, harnessing the power of AI and cutting-edge technology to redefine patient care and drug development. Join us at this exclusive event to explore the pivotal role of AI in advancing monoclonal antibodies (mAbs), transforming clinical trials, and driving the future of biopharma with the Biosecure Act. ✨ Event Highlights: 🔬 From Concept to Care: How AI is revolutionizing mAbs development 🤝 Shaping the Future of Biopharma: The strategic role of CROs, CDMOs, and the Biosecure Act 🌍 Innovation & Collaboration: Maximizing impact through ecosystem partnerships 👥 Who Should Attend? CXOs, VPs, Directors, Heads in R&D, Quality Control, Smart Manufacturing, and Procurement. 🚀 Why Attend? •⁠ ⁠Knowledge Sharing: Gain insights from industry leaders on the latest trends and best practices in digital biopharma. •⁠ ⁠Exploration of Technologies: Discover how AI, ML, and data analytics are shaping the future of biopharma R&D. •⁠ ⁠Collaboration Opportunities: Network with senior leaders and decision-makers in the biopharma sector. •⁠ ⁠Future Trends: Stay ahead of the curve with insights into the next era of biopharma innovations. Don't miss out on the opportunity to be at the forefront of biopharma's digital transformation. Let's drive the future of healthcare innovation together! 💡 🔗 Register Now > https://lnkd.in/dEKSE9AK (*By Invitation Only) Beckman Coulter Life Sciences | BlueTech Media . #BiopharmaInnovation #AIinHealthcare #DrugDevelopment #BiopharmaLeadership #NetworkingOpportunities #MonoclonalAntibodies #FutureOfHealthcare

We are pleased to welcome Trinity Biotech plc to the B2i Digital family of Featured Companies https://lnkd.in/d3m_BMKB. An established leader in the international diagnostics market, Trinity Biotech (Nasdaq: TRIB) has built an impressive portfolio of over 400 products since its founding in 1992. Trinity Biotech specializes in developing, manufacturing, and marketing diagnostic test kits for clinical laboratory and point-of-care settings. Their comprehensive product line includes solutions for infectious diseases, sexually transmitted diseases, autoimmune disorders, hemoglobin testing, and diabetes monitoring. The company has recently expanded into the biosensor market through strategic acquisition, positioning itself for growth in continuous glucose monitoring technology. With manufacturing facilities spanning Europe and America - including operations in Bray, Ireland; Kansas City, Missouri; Buffalo, New York; Jamestown, New York; and Brazil - Trinity Biotech serves a global market reaching more than 100 countries through direct sales and distributor networks. The company is undergoing a comprehensive transformation program to enhance operational efficiency while developing new opportunities in the rapidly growing biosensor market. Their recent entry into continuous glucose monitoring technology represents a strategic move into a market projected to reach $13 Billion by 2029. For more about Trinity Biotech, please visit https://lnkd.in/gc-5AjX9 and stay tuned to B2i Digital for updates. Trinity is led by a senior management team with decades of experience, including John Gillard, CEO, Louise Kilpatrick Tallon, CFO, Cormac Reynolds , VP of Operations, Ian Wells, VP of Quality Assurance and Regulatory Affairs, Colm Molloy, Global Director of HR, Training & Culture, John Mee, Global Director of Supply Chain, and Gary Keating, PhD, Chief Technology Officer. For investor-related questions, please contact Eric Ribner, LifeSci Partners, at investorrelations@trinitybiotech.com. #TrinityBiotech #Diagnostics #MedTech #HealthcareTech #BioTechnology #B2iDigital

Are you looking to expand your business network and showcase your solutions to top-tier industry leaders? 📈 At hubXchange we create exclusive, invitation-only Xchanges where C-level executives from some of the world’s most innovative life science organizations come together to share knowledge and explore meaningful partnerships. If your company is seeking to position itself as a leader in the life science sector, partnering with hubXchange is your gateway to: ✅ Tailored Engagements: Gain face-to-face access to key decision-makers through curated, small group discussions. ✅ Brand Exposure: Strengthen your company's position as an industry thought leader and build lasting relationships with high-level stakeholders. ✅ Unmatched ROI: Connect with clients ready to take action, optimizing both your time and resources. Our partners have found unparalleled value in these opportunities, leading to meaningful collaborations, investments, and growth. Take your business to the next level with hubXchange. 📅 Ready to partner? Visit our website to learn more about how hubXchange can help you thrive in today’s competitive life sciences market: https://lnkd.in/e2XdDXNs Partnership opportunities for Europe 2024 & San Diego 2025 events now open! ✅ Don't miss your chance to participate in our upcoming events: MARYLAND 2024 🟡 Antibody Therapeutics Xchange Brussels | 18 Nov 2024 🟣 Immunotherapies Xchange Brussels | 19 Nov 2024 🟠 Nucleic Acid Therapeutics Xchange Brussels | 20 Nov 2024 🔵 AI in Drug Discovery Xchange Brussels | 21 Nov 2024 SAN DIEGO 2025 🟡 Antibody Therapeutics Xchange San Diego | 17 Feb 2025 🟣 Immunotherapies Xchange San Diego| 18 Feb 2025 🔵 AI in Drug Discovery Xchange San Diego | 20 Feb 2025 🟢 Advanced Therapies Xchange San Diego | 21 Feb 2025 Clarence Maguire-Swartz, Jethro Curtis, Robert Lishmund #LifeSciences #BusinessPartnerships #Innovation #Networking #hubXchange #IndustryLeaders #Partnerships #Biotech #Pharma #Roundtables #NewPartnerships #SponsorCallout #NewWayToNetwork

🌐 Join Us at the Cutting Edge of Biopharma Innovation! 🌐 India is emerging as a global leader in the biopharma landscape, harnessing the power of AI and cutting-edge technology to redefine patient care and drug development. Join us at this exclusive event to explore the pivotal role of AI in advancing monoclonal antibodies (mAbs), transforming clinical trials, and driving the future of biopharma with the Biosecure Act. ✨ Event Highlights: 🔬 From Concept to Care: How AI is revolutionizing mAbs development 🤝 Shaping the Future of Biopharma: The strategic role of CROs, CDMOs, and the Biosecure Act 🌍 Innovation & Collaboration: Maximizing impact through ecosystem partnerships 👥 Who Should Attend? CXOs, VPs, Directors, Heads in R&D, Quality Control, Smart Manufacturing, and Procurement. 🚀 Why Attend? •⁠ ⁠Knowledge Sharing: Gain insights from industry leaders on the latest trends and best practices in digital biopharma. •⁠ ⁠Exploration of Technologies: Discover how AI, ML, and data analytics are shaping the future of biopharma R&D. •⁠ ⁠Collaboration Opportunities: Network with senior leaders and decision-makers in the biopharma sector. •⁠ ⁠Future Trends: Stay ahead of the curve with insights into the next era of biopharma innovations. Don't miss out on the opportunity to be at the forefront of biopharma's digital transformation. Let's drive the future of healthcare innovation together! 💡 🔗 Register Now > https://lnkd.in/dEKSE9AK (*By Invitation Only) Beckman Coulter Life Sciences | BlueTech Media #BiopharmaInnovation #AIinHealthcare #DrugDevelopment #BiopharmaLeadership #NetworkingOpportunities #MonoclonalAntibodies #FutureOfHealthcare

The life-science ecosystem of Wallonia (Southern Belgium) was showcased at the LSX World Congress by a panel of experts: Benoit Kenda, VP and Early Solution Partnering Head at UCB; Amel Tounsi, CEO of Bridge to Health; and Marc Foidart, Executive Chairman of EyeD Pharma. They offered a fresh perspective on the current investment and partnering landscapes within Europe, with a focus on Wallonia, Belgium. Find out more on the strategies and challenges involved in scaling up biotech innovations, the strengths and characteristics of Belgium and Wallonia's biotech ecosystem and the benefits and advantages to forming new partnerships within Belgium and the Walloon region. We are proud to have our life sciences ecosystem represented by such an impressive group of experts! UCB Bridge to Health (B2H) EyeD Pharma Wallonie Bruxelles International AWEX UK Wallonie-Bruxelles International - Research and Innovation Noshaq Pascale Delcomminette Bioxodes convEyXO EXO Biologics CorQuest MedTech Allyfe Gabi SmartCare Bio-Sourcing ODIX medical Amyl Therapeutics Bloomlife Inc neuroClues #biotech #innovation #investment #healthtech #healthcarerevolution #lifesciences

🌟 Highlights from Day Three at BIO International Convention: 📢 Amgen CEO Bob Bradway on the ‘Innovation Reduction Act’ Bradway expressed concerns about the IRA's impact on biotech innovation, particularly its shortened timeframe for small molecules. He emphasized the need for better support for preventative therapies. 📢 Novo Nordisk’s BD Strategy: Opportunities Over Cash Novo Nordisk's John McDonald discussed leveraging their financial strength from semaglutide success. While there's no budget limit for BD, the focus is on quality opportunities and partnerships over large acquisitions. 📢 Roivant Sciences: No Rush to Sell Immunovant’s FcRn Candidate CEO Matt Gline highlighted Roivant’s strategic patience with Immunovant’s FcRn inhibitor, IMVT-1402, bolstered by strong financials from a prior Roche deal. Roivant is keen on exploring the asset’s potential before making any decisions. 📢 AI Experts Discuss Global Regulatory Considerations Chris Hart of Foley Hoag LLP and other experts discussed the fragmented US AI regulation versus the comprehensive EU approach. Challenges like AI data structuring and interoperability were emphasized, along with managing AI hallucinations through collaboration and benchmarking. #BIO24 #Innovation #Healthcare #Pharma #AI #Regulation #Amgen #NovoNordisk #RoivantSciences #BusinessDevelopment #ClinicalTrials #TechPolicy #Biotech #Strategy #PreventativeCare #Citeline #InflationReductionAct

🌐 Join us in welcoming our esteemed speaker, Dr. Kasinath Viswanathan PhD, Head, In Vitro Biology, Drug Discovery Research, Zydus Research Centre to the Cutting Edge of Biopharma Innovation Summit! 🌐 India is emerging as a global leader in the biopharma landscape, harnessing the power of AI and cutting-edge technology to redefine patient care and drug development. Join us at this exclusive event to explore the pivotal role of AI in advancing monoclonal antibodies (mAbs), transforming clinical trials, and driving the future of biopharma with the Biosecure Act. ✨ Event Highlights: 🔬 From Concept to Care: How AI is revolutionizing mAbs development 🤝 Shaping the Future of Biopharma: The strategic role of CROs, CDMOs, and the Biosecure Act 🌍 Innovation & Collaboration: Maximizing impact through ecosystem partnerships 👥 Who Should Attend? CXOs, VPs, Directors, Heads in R&D, Quality Control, Smart Manufacturing, and Procurement. 🚀 Why Attend? •⁠ ⁠Knowledge Sharing: Gain insights from industry leaders on the latest trends and best practices in digital biopharma. •⁠ ⁠Exploration of Technologies: Discover how AI, ML, and data analytics are shaping the future of biopharma R&D. •⁠ ⁠Collaboration Opportunities: Network with senior leaders and decision-makers in the biopharma sector. •⁠ ⁠Future Trends: Stay ahead of the curve with insights into the next era of biopharma innovations. Don't miss out on the opportunity to be at the forefront of biopharma's digital transformation. Let's drive the future of healthcare innovation together! 💡 🔗 Register Now > https://lnkd.in/dEKSE9AK (*By Invitation Only) Beckman Coulter Life Sciences | BlueTech Media . #BiopharmaInnovation #AIinHealthcare #DrugDevelopment #BiopharmaLeadership #NetworkingOpportunities #MonoclonalAntibodies #FutureOfHealthcare

Excited for the 7th Alcor Drug Discovery Platform Summit under the esteemed leadership of our Chairman for Day 1, Abdulkader Rahmo, who serves as President & CSO SMSbiotech. As we convene for this premier event, we embark on a collective journey of exploration, collaboration, and innovation in the dynamic realm of drug discovery. Under Chairman Rahmo's visionary guidance, this summit promises to be a nexus of cutting-edge research, insightful discussions, and invaluable networking opportunities. Join us as we unite with leading experts, industry pioneers, and visionaries to chart the course for the future of drug discovery. This summit isn't just about presentations—it's a convergence of minds dedicated to driving progress, shaping the future, and making a meaningful impact on global health. Let's elevate the discourse, ignite innovation, and propel the field of drug discovery to new heights. Together, we're shaping a healthier, brighter tomorrow. #AlcorDrugDiscovery #Summit #Innovation #ADDP2024 #DrugDiscovery #Preclinical #LifeSciencesSummits #DrugDiscovery #PreclinicalSummits #USADrugDiscoverySummits

Paul Wiggermann, site manager at Roche Penzberg, describes the newly laid Diagnostics Production Center as a transformative step for the site. 🔬 This advanced facility will enhance Roche’s capabilities in diagnostics and biopharmaceutical production, positioning Penzberg as a key player in global healthcare innovation. With over 7,200 highly skilled professionals, the Penzberg site is one of Europe’s largest biotechnology hubs, reinforcing Roche's commitment to advancing personalized medicine while contributing to both the local and global economy. By laying the foundation for this new center, @Roche underscores its dedication to innovation and sustainability, further solidifying Bavaria’s reputation as a leader in life sciences and diagnostics. 👩🔬 🌍 Healthcare in Bavaria is recognized for its robust innovation ecosystem, which combines cutting-edge research, high-quality medical facilities, and strong collaboration between universities, research institutions, and the private sector. The region is home to renowned medical clusters like the BioM Biotech Cluster Development GmbH, the BioPark Regensburg GmbH, IZB - Innovation and Start-up Center Biotechnology and the Medical Valley EMN e. V., fostering advancements in personalized medicine, digital health, and biopharmaceuticals. Bavaria’s healthcare sector continues to attract top-tier companies and talent, strengthening its position as a leading destination for global healthcare innovation. 💡 More about healthcarein Bavaria: https://lnkd.in/dhKy-n-y Roche Deutschland #SuccessinBavaria #HealthCare #LifeSciences